Showing results (81-90 of 229) with videos related to

Sort By:
Pageof 23
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 22, 2006
Long-term performance of interstial fluid pressure and hypoxia as prognostic factors in cervix cancerAnthony Fyles, Michael Milosevic, Melania Pintilie, et al.
Clinical and Translational Radiation Oncology|October 26, 2019
Intratumoral heterogeneity and hypoxia gene expression signatures: Is a single biopsy adequate?Jelena Lukovic, Kathy Han, Melania Pintilie, et al.
Nature Communications|May 13, 2026
Maveropepimut-S, pembrolizumab and low dose cyclophosphamide in metastatic ovarian cancer: phase 1/2 PESCO trialAna C Veneziani, Stephanie Lheureux, Douglas G Millar, et al.
International Journal of Radiation Oncology, Biology, Physics|July 4, 2002
Stage II endometrial carcinoma: prognostic factors and risk classification in 170 patientsGraham Pitson, Terence Colgan, Wilfred Levin, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 31, 2011
Patient-specific PTV margins in radiotherapy for bladder cancer - a feasibility study using cone beam CTShaun Tolan, Vickie Kong, Tara Rosewall, et al.
The Canadian Journal of Urology|March 12, 2002
Clinical and biochemical outcome of conventional dose radiotherapy for localized prostate cancerCharles Catton, Mary Gospodarowicz, Jimmy Mui, et al.
BMC Cancer|January 9, 2008
Interstitial fluid pressure, vascularity and metastasis in ectopic, orthotopic and spontaneous tumoursSarah Jane Lunt, Tuula Mk Kalliomaki, Allison Brown, et al.
Practical Radiation Oncology|September 7, 2014
Deriving patient-specific planning target volume for partial bladder image guided radiation therapyVickie Kong, Tara Rosewall, Susan Chen, et al.
Frontiers in Oncology|August 19, 2024
Multiparametric MRI radiomics for predicting disease-free survival and high-risk histopathological features for tumor recurrence in endometrial cancerMary Renton, Mina Fakhriyehasl, Jessica Weiss, et al.
Cancer Research|February 21, 2006
Effects of the vascular disrupting agent ZD6126 on interstitial fluid pressure and cell survival in tumorsJulia V Skliarenko, Sarah Jane Lunt, Maggie L Gordon, et al.
Pageof 23